CXCL16 and lung cancer: (108) found that CXCL16 participated in the blockage of the complement C5A/C5AR axis in lung cancer bone metastasis, suggesting that CXCL16 is also a potential biomarker for the prediction of lung cancer progression and bone metastasis.